Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon Jun 19, 2019 1:58pm
57 Views
Post# 29840839

RE:RE:RE:RE:RE:RE:Sesen (SESN.Q)

RE:RE:RE:RE:RE:RE:Sesen (SESN.Q)Bunge ... You'd probably have to fired all TMX-V CEOs, with your example.

By the way, what's the ROI of your PMN stock, despite very promising data and news releases?

5Y chart (2014 to now) shows no progress in the share price.  

June 2014: 0.33$
Jan. 2018: 0.50$ (all time high)
Now: 0.25$

https://stockhouse.com/companies/quote?symbol=t.pmn

So how is that so different than TLT? 

Were you as arrogant on their CEO, as impatient about the share price movement and grumbling about the market valuation ("we should be tradin much higher")?  I remember reading you and being so excited when the stock price moved from 0.20$ to 0.50$ in 1 month between Dec. 30 2017 to Feb. 3, 2018.  Then, the gradual pullback to 0.20$ by Dec. 2018.

5Y chart comparison between TLT and PBM gives this:

TLT: +44%
PMN: -21%

I know, I know.  You were in PMN @0.05$.  But that doesn't change much the picture.  PMN is not much ahead, when compared to TLT.

Latest News

ProMIS Names Award-Winning Researcher to Advisory Board

Stockhouse Editorial 4 hours ago
3 stars
 

ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board

Canada NewsWire 6 hours ago
3 stars
 

ProMIS to Present Alzheimer’s Program Data at Premier Event

Stockhouse Editorial 13 days ago
3 stars
 

ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

Canada NewsWire June 5, 2019
3 stars
 

ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative Diseases

Canada NewsWire May 29, 2019



_______________

Bunge - (6/19/2019 1:26:20 PM) 
RE:RE:RE:RE:RE:Sesen (SESN.Q)
floatinketucky wrote:Some posts are so silly they are not even worth my time. I'll check back in a few weeks. 
Also the compnay is in line with time guidelines. 

Actually i'll check back in maybe someone call tell me what guideance they have missed. 
We can discuss.


It’s carryover from Roger’s CEO (Korelin interview) days.

Why people keep harping on it (and bringing up shareholders’ frustration about it at the time) YEARS later is beyond me.

Example: Roger’s $10M/yr therapeutic sales. Who has even talked about that for years? Basically nobody except a few posters to instill FUD or stir up the past to insult other shareholders. Water under the bridge though.

#goTLTgo

Bullboard Posts